Alcon Buys Aerie Pharma For $770M To Enhance Its Ophthalmic Pharma Portfolio
Alcon AG (NYSE:ALC) has agreed to acquire Aerie Pharmaceuticals Inc (NASDAQ:AERI) for $15.25 per share, valuing Aerie at about $770 million. The…
Facebook Co-Founder’s VC Firm Leads $20M Funding Round For Indian Health-Tech Startup
Facebook Inc (NASDAQ: FB) co-founder Eduardo Saverin and Raj Ganguly’s venture capital firm B Capital Group has led Series-A funding round for Indian health-tech start-up Mojocare which is cl
Bill Gates Gives Sendoff To Fauci: ‘You Are A Hero To Millions, Including Me’
Dr. Anthony Fauci, who has been the face of the U.S. government's drive against the COVID-19 pandemic, announced Monday he would quit his three federal government positions by December.
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery…
Geron Commences Initial-Stage Rare Blood Cancer Combination Study
Geron Corporation (NASDAQ: GERN) has dosed first patient in IMproveMF study evaluating imetelstat in combination with ruxolitinib for patients with frontline myelofibrosis (MF).
HC Wainwright Cuts Price For This Small Cap ‘Reflecting Potential Pause In Hemophilia Program’
Earlier this month, Freeline Therapeutics Holdings PLC (NASDAQ: FRLN) reported 2Q22 earnings focusing on the pipeline’s progress. Notably, the company said it…
Why Pharvaris Shares Are Plummeting Today?
The FDA verbally placed a clinical hold on Pharvaris NV’s (NASDAQ:PHVS) PHA121 in the U.S. under two Pharvaris Investigational New Drug (IND)…
HC Wainwright Is Bullish On This Multiple Myeloma Focused Stock
HC Wainwright increased the price target on Genmab A/S (NASDAQ:GMAB) from $49 to $51, with a Buy rating. The analyst cites that…
Turnaround For This Cancer Genetics Testing Firm Could Take Years, Analyst Says While Downgrading Stock
Needham has downgraded NeoGenomics Inc (NASDAQ:NEO) from Buy to Hold, citing that NEO’s turnaround will likely take several years and believes…
Kronos Bio Shares Fall After Initial-Stage Blood Cancer Study Takes-off
Kronos Bio (NASDAQ: KRON) has initiated patient dosing in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).